NEW YORK (360Dx) – Breathalyzer-based diagnostic firm Owlstone Medical today said it has raised approximately $11.6 million in an investment round.

Existing investors participated in the round, which will go toward a commercial launch of Owlstone's breath biomarker R&D services, including the opening of a new high-volume clinical facility, the Cambridge, UK-based company said. Funds will also be used for ongoing clinical trials in lung and colon cancer screening.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.